158 related articles for article (PubMed ID: 38762534)
1. Evaluation of the clinical use of MGMT methylation in extracellular vesicle-based liquid biopsy as a tool for glioblastoma patient management.
Rosas-Alonso R; Colmenarejo-Fernández J; Pernía O; Burdiel M; Rodríguez-Antolín C; Losantos-García I; Rubio T; Moreno-Velasco R; Esteban-Rodríguez I; Martínez-Marín V; Yubero P; Costa-Fraga N; Díaz-Lagares A; López-López R; Díaz-Martin E; García JF; Sánchez CV; Gandía-González ML; Moreno-Bueno G; de Castro J; de Cáceres II
Sci Rep; 2024 May; 14(1):11398. PubMed ID: 38762534
[TBL] [Abstract][Full Text] [Related]
2. Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.
Kessler T; Sahm F; Sadik A; Stichel D; Hertenstein A; Reifenberger G; Zacher A; Sabel M; Tabatabai G; Steinbach J; Sure U; Krex D; Grosu AL; Bewerunge-Hudler M; Jones D; Pfister SM; Weller M; Opitz C; Bendszus M; von Deimling A; Platten M; Wick W
Neuro Oncol; 2018 Feb; 20(3):367-379. PubMed ID: 29016808
[TBL] [Abstract][Full Text] [Related]
3. Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
Hallaert G; Pinson H; Vanhauwaert D; Van den Broecke C; Van Roost D; Boterberg T; Kalala JP
Surg Oncol; 2020 Dec; 35():515-519. PubMed ID: 33152608
[TBL] [Abstract][Full Text] [Related]
4. The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival.
Shu C; Wang Q; Yan X; Wang J
Cancer Med; 2018 Aug; 7(8):3704-3712. PubMed ID: 29984907
[TBL] [Abstract][Full Text] [Related]
5. Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker.
Preusser M; Charles Janzer R; Felsberg J; Reifenberger G; Hamou MF; Diserens AC; Stupp R; Gorlia T; Marosi C; Heinzl H; Hainfellner JA; Hegi M
Brain Pathol; 2008 Oct; 18(4):520-32. PubMed ID: 18400046
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of MGMT promoter methylation on the survival of TMZ treated
Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
[TBL] [Abstract][Full Text] [Related]
7. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas.
Haque W; Thong E; Andrabi S; Verma V; Brian Butler E; Teh BS
J Clin Neurosci; 2021 Mar; 85():115-121. PubMed ID: 33581781
[TBL] [Abstract][Full Text] [Related]
9. [Clinical, immunohistochemical, and molecular genetic prognostic factors in adult patients with glioblastoma].
Lobanova NV; Shishkina LV; Ryzhova MV; Kobyakov GL; Sycheva RV; Burov SA; Lukyanov AV; Omarova ZR
Arkh Patol; 2016; 78(4):10-19. PubMed ID: 27600777
[TBL] [Abstract][Full Text] [Related]
10. Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients.
Tang K; Jin Q; Yan W; Zhang W; You G; Liu Y; Jiang T
Med Oncol; 2012 Jun; 29(2):1292-6. PubMed ID: 21394635
[TBL] [Abstract][Full Text] [Related]
11. Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients.
Balańa C; Carrato C; Ramírez JL; Cardona AF; Berdiel M; Sánchez JJ; Tarón M; Hostalot C; Musulen E; Ariza A; Rosell R
Clin Transl Oncol; 2011 Sep; 13(9):677-85. PubMed ID: 21865140
[TBL] [Abstract][Full Text] [Related]
12. The significance of MGMT methylation in Glioblastoma Multiforme prognosis.
Rao AM; Quddusi A; Shamim MS
J Pak Med Assoc; 2018 Jul; 68(7):1137-1139. PubMed ID: 30317322
[TBL] [Abstract][Full Text] [Related]
13. Pathology: commonly monitored glioblastoma markers: EFGR, EGFRvIII, PTEN, and MGMT.
Camara-Quintana JQ; Nitta RT; Li G
Neurosurg Clin N Am; 2012 Apr; 23(2):237-46, viii. PubMed ID: 22440867
[TBL] [Abstract][Full Text] [Related]
14. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J
Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743
[TBL] [Abstract][Full Text] [Related]
15. Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.
Jung TY; Jung S; Moon KS; Kim IY; Kang SS; Kim YH; Park CS; Lee KH
Oncol Rep; 2010 May; 23(5):1269-76. PubMed ID: 20372840
[TBL] [Abstract][Full Text] [Related]
16. Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients.
Radke J; Koch A; Pritsch F; Schumann E; Misch M; Hempt C; Lenz K; Löbel F; Paschereit F; Heppner FL; Vajkoczy P; Koll R; Onken J
Acta Neuropathol Commun; 2019 Jun; 7(1):89. PubMed ID: 31167648
[TBL] [Abstract][Full Text] [Related]
17. Combined analysis of MGMT methylation and dynamic-susceptibility-contrast MRI for the distinction between early and pseudo-progression in glioblastoma patients.
Bani-Sadr A; Berner LP; Barritault M; Chamard L; Bidet CM; Eker OF; Hermier M; Guyotat J; Jouanneau E; Meyronet D; Gouttard S; D'Hombres A; Iziquierdo C; Honnorat J; Berthezène Y; Ducray F
Rev Neurol (Paris); 2019 Oct; 175(9):534-543. PubMed ID: 31208813
[TBL] [Abstract][Full Text] [Related]
18. Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics.
Jiang S; Rui Q; Wang Y; Heo HY; Zou T; Yu H; Zhang Y; Wang X; Du Y; Wen X; Chen F; Wang J; Eberhart CG; Zhou J; Wen Z
Eur Radiol; 2018 May; 28(5):2115-2123. PubMed ID: 29234914
[TBL] [Abstract][Full Text] [Related]
19. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.
Lalezari S; Chou AP; Tran A; Solis OE; Khanlou N; Chen W; Li S; Carrillo JA; Chowdhury R; Selfridge J; Sanchez DE; Wilson RW; Zurayk M; Lalezari J; Lou JJ; Ormiston L; Ancheta K; Hanna R; Miller P; Piccioni D; Ellingson BM; Buchanan C; Mischel PS; Nghiemphu PL; Green R; Wang HJ; Pope WB; Liau LM; Elashoff RM; Cloughesy TF; Yong WH; Lai A
Neuro Oncol; 2013 Mar; 15(3):370-81. PubMed ID: 23328811
[TBL] [Abstract][Full Text] [Related]
20. Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.
Han Y; Yan LF; Wang XB; Sun YZ; Zhang X; Liu ZC; Nan HY; Hu YC; Yang Y; Zhang J; Yu Y; Sun Q; Tian Q; Hu B; Xiao G; Wang W; Cui GB
BMC Cancer; 2018 Feb; 18(1):215. PubMed ID: 29467012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]